XELOX vs. FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer

Basit Öğe Kaydı
dc.contributor.authorBerk, Veli
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorOzkan, Metin
dc.contributor.authorAksoy, Sercan
dc.contributor.authorTuran, Nedim
dc.contributor.authorInal, Ali
dc.contributor.authorBalakan, Ozan
dc.date.accessioned2024-04-24T17:28:03Z
dc.date.available2024-04-24T17:28:03Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/Aims: The efficacy and tolerability of oxaliplatin in combination with either folinic acid, fluorouracil (5-FU) (FOLFOX4 regimen) or capecitabine (XELOX regimen) was evaluated in advanced pancreatic cancer. Methodology: In this study, eighty-five patients with advanced pancreatic cancer were enrolled after failing to gemcitabine-based chemotherapy between November 2005 and August 2011. FOLFOX4 was repeated every two weeks and XELOX regimen was repeated every three weeks until either disease progression or unacceptable toxicity occurred. Results: Eighty-five patients were evaluated for tumor response. Seven patients (18%) achieved a partial response with XELOX and stable disease was observed in 16 patients (41%). Eight patients (17%) achieved a partial response with FOLFOX4 and stable disease was observed in 12 patients (26%). Disease control rates were 59% in the XELOX arm and 43% in the FOLFOX4 arm. The median time to progression was 16 weeks in both arms. The median overall survival was 21 weeks with XELOX and 25 weeks with FOLFOX4. Conclusions: Oxaliplatin-based combination therapy showed moderate clinical activity with acceptable toxicity in patients who had progressive disease after receiving gemcitabine-based chemotherapy for advanced and/or metastatic pancreatic cancer. We conclude that XELOX is similar in terms of efficacy and toxicity profile to FOLFOX4 in the second-line treatment of metastatic pancreatic cancer.en_US
dc.identifier.doi10.5754/hge12181
dc.identifier.endpage2639en_US
dc.identifier.issn0172-6390
dc.identifier.issue120en_US
dc.identifier.pmid22534542
dc.identifier.scopus2-s2.0-84871234387
dc.identifier.scopusqualityN/A
dc.identifier.startpage2635en_US
dc.identifier.urihttps://doi.org/10.5754/hge12181
dc.identifier.urihttps://hdl.handle.net/11468/20306
dc.identifier.volume59en_US
dc.identifier.wosWOS:000312689300061
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherH G E Update Medical Publishing S Aen_US
dc.relation.ispartofHepato-Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject5-Fluorouracilen_US
dc.subjectOxaliplatinen_US
dc.subjectCapecitabineen_US
dc.subjectPancreatic Canceren_US
dc.titleXELOX vs. FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Canceren_US
dc.titleXELOX vs. FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu